Methods and compositions for treating metabolic syndrome

• US 9,089,579 B2
• Filed: 01/18/2012
• Issued: 07/28/2015
• Est. Priority Date: 01/19/2011
• Status: Active Grant

• Current Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Original Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Inventors: Kalayoglu, Murat V.
• Primary Examiner(s): Padmanabhan, Sreeni
• Assistant Examiner(s): Neagu, Irina
• Application Number:
  US13/980,179
• Publication Number:
  US 20140045933A1
• Time in Patent Office: 1,287 Days
• Field of Search: 514/573, 514/530, 560/121, 562/503
• US Class Current: 1/1
• CPC Class Codes: A61K 31/133 having hydroxy groups, e.g. sphingosine
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 31/5585 having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07C 235/30 the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
• CPC Class Codes: C07C 69/732 : of unsaturated hydroxy carboxylic acids
• CPC Class Codes: C07D 307/20 : Oxygen atoms

Abstract

Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein, L, R₁; R₂, Z, X, A and B are defined herein.

Claims

1. A method of treating a diabetic condition selected from the group consisting of type 2 diabetes mellitus and a complication of type 2 diabetes mellitus in a subject, comprising administering systemically and transdermally to the subject a therapeutically effective amount of a compound selected from the group consisting of:

2. The method of claim 1, wherein the diabetic condition is type 2 diabetes mellitus.

3. The method of claim 1, wherein the method improves glucose tolerance.

4. The method of claim 1, wherein the method reduces serum glucose.

5. The method of claim 1, wherein the method reduces glycated hemoglobin.

6. The method of claim 1, wherein the method reduces the subject'"'"'s need for insulin.

7. The method of claim 1, wherein the method treats a complication of type 2 diabetes mellitus in the subject.

8. The method of claim 7, wherein the complication of type 2 diabetes mellitus is selected from the group consisting of nephropathy, peripheral neuropathy, retinopathy, atherosclerosis, stroke, myocardial ischemia, infection, foot ulcers, acidosis, and coma.

9. The method of claim 1, wherein the compound is administered to the skin at a dose of between about 3 mg in a 24-hour period to about 50 mg in a 24-hour period, inclusive.

10. The method of claim 1, wherein the peak serum concentration of the compound or active metabolite thereof is between about 50 pg/ml and 1000 pg/ml.